Clarametyx 2022-01: Immunogenicity assessment of a peptide immunogen in naïve mice ¿ adjuvant screening

Project Details

StatusFinished
Effective start/end date6/01/225/01/23

Funding

  • Clarametyx Biosciences, Inc.: $8,642.00